HUP0402262A2 - Helyettesített ciklohexánszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Helyettesített ciklohexánszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0402262A2
HUP0402262A2 HU0402262A HUP0402262A HUP0402262A2 HU P0402262 A2 HUP0402262 A2 HU P0402262A2 HU 0402262 A HU0402262 A HU 0402262A HU P0402262 A HUP0402262 A HU P0402262A HU P0402262 A2 HUP0402262 A2 HU P0402262A2
Authority
HU
Hungary
Prior art keywords
lower alkyl
group
hydrogen atom
carbon
independently
Prior art date
Application number
HU0402262A
Other languages
English (en)
Inventor
Jean Ackermann
Johannes Aebi
Henrietta Dehmlow
Georges Hirth
Hans-Peter Maerki
Olivier Morand
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of HUP0402262A2 publication Critical patent/HUP0402262A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A találmány tárgyát az (I) általános képletű vegyületek, melyképletben U jelentése O vagy magányos elektronpár V jelentéseegyeskötés, O, S, -CH2-, -CH=CH-, -CH=CH-CH2-O- vagy -C<C- ; Wjelentése CO, COO, CONR1, CSO, CSNR1, SO2 vagy SO2NR1; m és njelentése egymástól függetlenül 0-7; és m+n összege 0-7; azzal afeltétellel, hogy ha V jelentése O vagy S, úgy m 0-tól eltérő értékű;A1 jelentése hidrogénatom, kis szénatomszámú alkil-, hidroxi-(kisszénatomszámú alkil)- vagy kis szénatomszámú alkenilcsoport; A2jelentése cikloalkil-, cikloalkil-kis szénatomszámú alkil-, kisszénatomszámú alkenil-, kis szénatomszámú alkinil-, heteroaril- vagyadott esetben R2 csoporttal helyettesített kis szénatomszámúalkilcsoport; vagy A1 és A2 együtt gyűrűt képez és -A1-A2-jelentéseadott esetben R2 csoporttal helyettesített kis szénatomszámú alkilén-vagy kis szénatomszámú alkeniléncsoport; mimellett az -A1-A2-csoportban levő egyik -CH2- csoport helyén adott esetben NR3, S vagy Olehet jelen; vagy -A1-A2- jelentése -CH=N-CH=CH-, amely adott esetbenkis szénatomszámú alkilcsoporttal helyettesítve lehet; A3 és A4jelentése egymástól függetlenül hidrogénatom vagy kis szénatomszámúalkilcsoport; vagy A3 és A4 a szénatommal együtt, amelyhezkapcsolódik, gyűrűt képez és -A3-A4-jelentése -(CH2)2-5- csoport; A5,A6, A7 és A8 jelentése egymástól függetlenül hidrogénatom vagy kisszénatomszámú alkilcsoport; A9 jelentése hidrogénatom, kisszénatomszámú alkil-, kis szénatomszámú alkenil vagy aril-kisszénatomszámú alkilcsoport; A10 jelentése kis szénatomszámú alkil-,cikloalkil-, aril-, aril-kis szénatomszámú alkil-, heteroaril- vagyheteroaril-kis szénatomszámú alkilcsoport; p értéke 0 vagy 1; R2jelentése hidroxi-, hidroxi-kis szénatomszámú alkil-, kisszénatomszámú alkoxi-, kis szénatomszámú alkoxi-karbonil-, N(R4,R5),tio-kis szénatomszámú alkoxicsoport vagy halogénatom; és R1, R3, R4 ésR5 jelentése egymástól függetlenül hidrogénatom vagy kis szénatomszámúalkilcsoport és gyógyászatilag alkalmas sóik képezik - kivéve atransz-naftalin-l-szulfonsav-metil-(4-metilaminometil-ciklohexilmetil)-amidot. A találmány szerinti vegyületek a 2,3-oxido-szkvalén-lanoszterol-cikláz inhibitorai, így az ezzel összefüggőbetegségek (pl. hiperkoleszterolémia, hiperlipémia, arterioszklerózis,érbetegségek, mikózisok, parazitafertőzések, epekövek, tumorok és/vagyhiperburjánzásos rendellenességek és/vagy károsodott glükóztoleranciaés diabétesz) kezelésére és/vagy megelőzésére alkalmazhatók. Ó
HU0402262A 2001-12-12 2002-12-05 Helyettesített ciklohexánszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk HUP0402262A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01129271 2001-12-12
PCT/EP2002/013786 WO2003053919A1 (en) 2001-12-12 2002-12-05 Substituted cyclohexane derivatives

Publications (1)

Publication Number Publication Date
HUP0402262A2 true HUP0402262A2 (hu) 2005-02-28

Family

ID=8179485

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402262A HUP0402262A2 (hu) 2001-12-12 2002-12-05 Helyettesített ciklohexánszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Country Status (26)

Country Link
US (2) US6953806B2 (hu)
EP (1) EP1456171B1 (hu)
JP (1) JP4124736B2 (hu)
KR (1) KR20040066896A (hu)
CN (1) CN100503560C (hu)
AR (1) AR037774A1 (hu)
AT (1) ATE348799T1 (hu)
AU (1) AU2002358096B2 (hu)
BR (1) BR0214939A (hu)
CA (1) CA2468879C (hu)
DE (1) DE60216967T2 (hu)
ES (1) ES2276974T3 (hu)
GT (1) GT200200271A (hu)
HR (1) HRP20040495A2 (hu)
HU (1) HUP0402262A2 (hu)
IL (1) IL162104A0 (hu)
MX (1) MXPA04005550A (hu)
NO (1) NO20042881L (hu)
PA (1) PA8560001A1 (hu)
PE (1) PE20030765A1 (hu)
PL (1) PL371471A1 (hu)
RU (1) RU2288221C2 (hu)
TW (1) TW200409623A (hu)
UY (1) UY27579A1 (hu)
WO (1) WO2003053919A1 (hu)
ZA (1) ZA200404547B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891002B1 (en) 2005-06-06 2012-05-30 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
US8703379B2 (en) * 2012-07-27 2014-04-22 Xerox Corporation Chemical binding of renewable oils to polyester emulsion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016738A1 (en) * 1989-06-08 1990-12-08 Philippe Guerry Substituted aminoalkylbenzene derivatives
DE4239151A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
AU1328197A (en) * 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
CA2190699A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
ES2223170T3 (es) * 1998-04-29 2005-02-16 Ortho-Mcneil Pharmaceutical, Inc. Aminotetralinas n sustituidas, ligandos del receptor y y5 del neuropeptido que sirve para el tratamiento de la obesidad y otros trastornos.

Also Published As

Publication number Publication date
US6953806B2 (en) 2005-10-11
ZA200404547B (en) 2006-02-22
JP4124736B2 (ja) 2008-07-23
GT200200271A (es) 2003-07-03
RU2288221C2 (ru) 2006-11-27
UY27579A1 (es) 2003-07-31
CN1604890A (zh) 2005-04-06
JP2005513127A (ja) 2005-05-12
AR037774A1 (es) 2004-12-01
DE60216967D1 (de) 2007-02-01
ATE348799T1 (de) 2007-01-15
PL371471A1 (en) 2005-06-13
HRP20040495A2 (en) 2005-06-30
CA2468879A1 (en) 2003-07-03
AU2002358096B2 (en) 2006-05-11
US20030199550A1 (en) 2003-10-23
IL162104A0 (en) 2005-11-20
AU2002358096A1 (en) 2003-07-09
ES2276974T3 (es) 2007-07-01
CN100503560C (zh) 2009-06-24
WO2003053919A1 (en) 2003-07-03
PE20030765A1 (es) 2003-09-11
KR20040066896A (ko) 2004-07-27
PA8560001A1 (es) 2004-04-23
NO20042881L (no) 2004-07-07
US20050272774A1 (en) 2005-12-08
DE60216967T2 (de) 2007-11-15
BR0214939A (pt) 2004-12-28
EP1456171B1 (en) 2006-12-20
EP1456171A1 (en) 2004-09-15
CA2468879C (en) 2009-05-19
MXPA04005550A (es) 2004-09-10
TW200409623A (en) 2004-06-16
RU2004121684A (ru) 2005-06-27

Similar Documents

Publication Publication Date Title
HUP0204580A2 (hu) Arilgyűrűvel kondenzált azapoliciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények
HUP0402310A2 (hu) 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
HUP0201646A2 (hu) Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
HUP0102851A2 (hu) Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0105437A2 (hu) Új malonsavszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0402503A2 (hu) Pirrolidinonszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
ATE260904T1 (de) ((cyclo)alkyl substituierte)-.gamma.- aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
HUP0001154A2 (hu) 3-Piperidil-4-oxo-kinazolin-származékok és a vegyületeket tartalmazó gyógyászati készítmények
HUP0204474A2 (hu) 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401537A2 (hu) Tiohidantoin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
HUP0101381A2 (hu) Benzofurilpironszármazékok és ezeket tartalmazó gyógyszerkészítmények
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
HUP0302157A2 (hu) 4-(2-Fenil-tiazol-5-il)-1,4-diazabiciklo[3.2.2]nonán-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
AR046705A1 (es) Pirido-7-pirimidin-7-onas substituidas con hidroxialquilo
HUP0303105A2 (hu) Új amino-ciklohexán-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0100102A2 (hu) Fenil-amino-alkilkarbonsav-származékok és fenil-amino-alkilkarbonsav-származékokat tartalmazó gyógyszerészeti készítmények
HUP0402262A2 (hu) Helyettesített ciklohexánszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PT871626E (pt) Triazolonas utilizadas como inibidores de sintese da apoliproteina b
ITMI932189A1 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
HUP0103166A2 (hu) Karbamát- és karbamidtartalmú készítmények, és neurotróf alkalmazásuk
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees